Community Acquired Pneumonia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Community Acquired Pneumonia - Pipeline Review, H2 2016

Community Acquired Pneumonia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Community Acquired Pneumonia - Pipeline Review, H2 2016
Published Jul 13, 2016
111 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Community Acquired Pneumonia - Pipeline Review, H2 2016, provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise correcti

  
Source:
Document ID
GMDHC8274IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Community Acquired Pneumonia Overview91
Therapeutics Development101
  Pipeline Products for Community Acquired Pneumonia Overview101
Community Acquired Pneumonia Therapeutics under Development by Companies111
Community Acquired Pneumonia Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Community Acquired Pneumonia Products under Development by Companies152
Community Acquired Pneumonia Companies Involved in Therapeutics Development1716
  Aridis Pharmaceuticals LLC171
  BioAegis Therapeutics, Inc.181
  Biotest AG191
  C10 Pharma AS201
  InflaRx GmbH211
  ioGenetics, Inc.221
  Kyorin Pharmaceutical Co., Ltd.231
  Lascco SA241
  Melinta Therapeutics, Inc251
  Merck &Co., Inc.261
  Nabriva Therapeutics AG271
  Paratek Pharmaceuticals, Inc.281
  TaiGen Biotechnology Co., Ltd.291
  Takeda Pharmaceutical Company Limited301
  Tetraphase Pharmaceuticals Inc.311
  TiGenix NV321
Community Acquired Pneumonia Therapeutics Assessment339
  Assessment by Monotherapy Products331
  Assessment by Target342
  Assessment by Mechanism of Action362
  Assessment by Route of Administration382
  Assessment by Molecule Type402
Drug Profiles4255
  BT-086 Drug Profile421
  C-10 Drug Profile431
  CAL-02 Drug Profile441
  ceftaroline fosamil Drug Profile453
  Cx-611 Drug Profile484
  DBAF-301 Drug Profile521
  delafloxacin Drug Profile538
  IFX-1 Drug Profile612
  KRPAM-1977X Drug Profile632
  KRPAM-1977Y Drug Profile651
  lefamulin acetate Drug Profile663
  nemonoxacin Drug Profile693
  omadacycline tosylate Drug Profile726
  PneumoMab Drug Profile781
  radezolid Drug Profile793
  Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia Drug Profile821
  solithromycin Drug Profile8310
  tosatoxumab Drug Profile932
  TP-271 Drug Profile952
Community Acquired Pneumonia Dormant Projects971
Community Acquired Pneumonia Discontinued Products981
Community Acquired Pneumonia Product Development Milestones9911
  Featured News &Press Releases991
    Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia991
    Jun 20, 2016: Nabriva Presents Data on Lefamulin at the American Society of Microbiology Microbe 2016 Conference991
    Jun 16, 2016: Cempra to Host Analyst and Investor Day on June 23, 20161001
    Jun 14, 2016: Melinta Therapeutics Presenting Results From Baxdela Programs At ASM Microbe 2016 Meeting1001
    Jun 13, 2016: TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn (nemonoxacin)1011
    Jun 10, 2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference1011
    May 31, 2016: Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients1021
    May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)1031
    May 16, 2016: Nabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference1041
    May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 20161051
    May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia1051
    Apr 11, 2016: Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin ( LEAP 2 ) in Patients with Community-Acquired Bacterial Pneumonia1061
    Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID1071
    Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets1071
    Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia1082
Appendix1102
  Methodology1101
  Coverage1101
  Secondary Research1101
  Primary Research1101
  Expert Panel Validation1101
  Contact Us1101
  Disclaimer1111

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Community Acquired Pneumonia - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Community-Acquired-Pneumonia-Pipeline-Review-H2-2016-2088-16175>
  
APA:
Global Markets Direct - Market Research. (2016). Community Acquired Pneumonia - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Community-Acquired-Pneumonia-Pipeline-Review-H2-2016-2088-16175>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.